BR112022005026A2 - Conjugados terapêuticos - Google Patents

Conjugados terapêuticos

Info

Publication number
BR112022005026A2
BR112022005026A2 BR112022005026A BR112022005026A BR112022005026A2 BR 112022005026 A2 BR112022005026 A2 BR 112022005026A2 BR 112022005026 A BR112022005026 A BR 112022005026A BR 112022005026 A BR112022005026 A BR 112022005026A BR 112022005026 A2 BR112022005026 A2 BR 112022005026A2
Authority
BR
Brazil
Prior art keywords
therapeutic conjugates
conjugates
therapeutic
administering
compositions
Prior art date
Application number
BR112022005026A
Other languages
English (en)
Inventor
Abellera Blair James
Sonin Dhawan Neil
B Perni Robert
Original Assignee
Totus Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Totus Medicines Inc filed Critical Totus Medicines Inc
Publication of BR112022005026A2 publication Critical patent/BR112022005026A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Abstract

conjugados terapêuticos. a presente invenção refere-se, de modo geral, a conjugados terapêuticos que se ligam covalentemente a um alvo biológico. também são fornecidos, neste documento, métodos de administração das composições a um indivíduo em necessidade.
BR112022005026A 2019-09-19 2020-09-18 Conjugados terapêuticos BR112022005026A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902554P 2019-09-19 2019-09-19
US202063078055P 2020-09-14 2020-09-14
PCT/US2020/051491 WO2021055747A1 (en) 2019-09-19 2020-09-18 Therapeutic conjugates

Publications (1)

Publication Number Publication Date
BR112022005026A2 true BR112022005026A2 (pt) 2022-06-21

Family

ID=74883745

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005026A BR112022005026A2 (pt) 2019-09-19 2020-09-18 Conjugados terapêuticos

Country Status (16)

Country Link
US (3) US20220387603A1 (pt)
EP (1) EP4031143A4 (pt)
JP (1) JP2022548135A (pt)
KR (1) KR20220079866A (pt)
CN (1) CN114599366A (pt)
AU (1) AU2020349543A1 (pt)
BR (1) BR112022005026A2 (pt)
CA (1) CA3154079A1 (pt)
CL (1) CL2022000665A1 (pt)
CO (1) CO2022003703A2 (pt)
IL (1) IL291486A (pt)
MX (1) MX2022003217A (pt)
PE (1) PE20230091A1 (pt)
TW (1) TW202126307A (pt)
WO (1) WO2021055747A1 (pt)
ZA (1) ZA202203201B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230091A1 (es) 2019-09-19 2023-01-16 Totus Medicines Inc Conjugados terapeuticos
EP4308121A1 (en) * 2021-03-18 2024-01-24 Totus Medicines Inc. Therapeutic conjugates
WO2023183936A2 (en) * 2022-03-24 2023-09-28 Totus Medicines Inc. Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof
WO2023179771A1 (en) 2022-03-24 2023-09-28 Totus Medicines Inc. Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
CN102159214A (zh) * 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
SG179085A1 (en) * 2009-09-09 2012-04-27 Avila Therapeutics Inc Pi3 kinase inhibitors and uses thereof
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
CA2799926A1 (en) 2010-05-28 2011-12-01 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
US20120231963A1 (en) 2011-03-10 2012-09-13 Raybiotech, Inc, Biotin-label-based antibody array for high-content profiling of protein expression
DK2710007T3 (da) * 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en) * 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN102675323B (zh) 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
CA2952287C (en) 2014-06-17 2023-05-16 Chiesi Farmaceutici S.P.A. Indolizine derivatives as phosphoinositide 3-kinases inhibitors
EP3191097B1 (en) * 2014-09-13 2019-10-23 Novartis AG Combination therapies
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN109111447A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
EP3661919A4 (en) 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS AND USES THEREOF
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
CN109081905A (zh) 2018-08-03 2018-12-25 浩力森涂料（上海）有限公司 水性环氧固化剂及其制备方法
WO2020052772A1 (en) 2018-09-13 2020-03-19 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Modulation of trf1 for brain cancer treatment
WO2020243457A1 (en) 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
PE20230091A1 (es) 2019-09-19 2023-01-16 Totus Medicines Inc Conjugados terapeuticos
WO2021243421A1 (en) 2020-06-05 2021-12-09 Monash University Dual kinase-bromodomain inhibitors

Also Published As

Publication number Publication date
CL2022000665A1 (es) 2022-10-28
CO2022003703A2 (es) 2022-07-08
US20220387603A1 (en) 2022-12-08
ZA202203201B (en) 2023-11-29
CA3154079A1 (en) 2021-03-25
PE20230091A1 (es) 2023-01-16
JP2022548135A (ja) 2022-11-16
EP4031143A1 (en) 2022-07-27
WO2021055747A1 (en) 2021-03-25
KR20220079866A (ko) 2022-06-14
MX2022003217A (es) 2022-06-29
TW202126307A (zh) 2021-07-16
AU2020349543A1 (en) 2022-03-24
US20220211855A1 (en) 2022-07-07
US20230096658A1 (en) 2023-03-30
US11484597B2 (en) 2022-11-01
CN114599366A (zh) 2022-06-07
IL291486A (en) 2022-05-01
EP4031143A4 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
BR112022005026A2 (pt) Conjugados terapêuticos
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
BR112019008854A2 (pt) ligantes contendo peptídeo para conjugados de anticorpo-fármaco
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
BR112013010544A2 (pt) moléculas de ligação ao egfr e imunoconjugados das mesmas
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
PE20160190A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112022000337A2 (pt) Conjugados de peptídeos de citotoxinas como terapêuticos
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
AU2017250507A8 (en) Methods of treatment using chlorotoxin conjugates
CL2018000131A1 (es) Inmunoconjugados de il22
BR112017018778A2 (pt) conjugados anticorpo-fármaco à base de criptoficina com ligantes autodegradantes inovadores
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas